Daiichi Sankyo Co. is in discussions to provide supplies of a potential coronavirus vaccine now being developed by AstraZeneca PLC and the University of Oxford for use in Japan.
The discussion follows a flurry of supply deals signed by the British drugmaker for its experimental COVID-19 vaccine as it ramps up efforts for wider trials of the potential treatment.
Daiichi Sankyo said in a statement on Friday that one of its subsidiaries would receive undiluted solution of the vaccine and then carry out formulation procedures, packaging, and storage in Japan. AstraZeneca said separately that it is in talks with the Japanese government on supplies of the potential vaccine, known as AZD1222.
Chief Cabinet Secretary Yoshihide Suga said earlier on Friday that the government is supporting domestic vaccine development but is also in negotiations with other parties.
“In any event, the government will work hard to ensure that Japan has the vaccines it needs,” Suga said.
In Japan, AnGes Inc. and Osaka University are working on a DNA vaccine for the novel coronavirus. Shionogi & Co. is working on a recombinant protein type, while the University of Tokyo and Daiichi Sankyo are developing an mRNA version.
AstraZeneca has doubled manufacturing and supply capacity for its potential vaccine to over 2 billion doses.
There are currently no approved vaccines or treatments for the illness caused by the new coronavirus, but about a dozen vaccines from more than 100 candidates globally are being tested in humans.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
Your news needs your support
Since the early stages of the COVID-19 crisis, The Japan Times has been providing free access to crucial news on the impact of the novel coronavirus as well as practical information about how to cope with the pandemic. Please consider subscribing today so we can continue offering you up-to-date, in-depth news about Japan.